Mallinckrodt and Endo are considering a $7 billion merger - Bloomberg

According to a Bloomberg report based on sources close to the matter, Mallinckrodt Pharmaceuticals and Endo Inc. are evaluating a potential merger valued at around $7 billion. Both pharmaceutical companies, which have emerged from bankruptcy and are facing lawsuits related to the opioid crisis in the U.S., are negotiating an agreement that would give each approximately 50% ownership in the combined entity.

The merger is expected to be finalized this week. According to sources who wish to remain anonymous due to the confidentiality of the talks, the new combined company is planned to be listed on the New York Stock Exchange. It’s important to note that discussions are ongoing and may not necessarily lead to a deal. Both Mallinckrodt and Endo representatives declined to comment on the matter.